08:36 AM EDT, 07/22/2025 (MT Newswires) -- Replimune Group ( REPL ) shares were down more than 77% in recent Tuesday premarket activity after the company said that the US Food and Drug Administration is "unable" to approve its biologics license application for RP1 in combination with nivolumab for advanced melanoma treatment.

Lockheed Martin ( LMT ) stock was down 7.6% after the company posted lower fiscal Q2 earnings and cut its 2025 EPS guidance.

Sarepta Therapeutics ( SRPT ) shares were 5% lower after the company said overnight it will voluntarily and temporarily pause all shipments of Elevidys in the US, effective close of business Tuesday.

NXP Semiconductors ( NXPI ) stock was down 4%, a day after the company reported lower fiscal Q2 non-GAAP earnings and revenue.